SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended October 31, 1999
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from _________________ to ___________________
Commission File Number 1-8366
------
POLYDEX PHARMACEUTICALS LIMITED
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Commonwealth of the Bahamas None
- --------------------------------------------------------------------------------
(State or Other Jurisdiction of (I.R.S. Employer
corporation or Organization) Identification No.)
421 Comstock Road, Toronto, Ontario, Canada M1L 2H5
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's Telephone Number, Including Area Code (416) 755-2231
------------------
- --------------------------------------------------------------------------------
Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report
Indicate by check whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No
----- -----
Indicate the number of shares outstanding of each of the issuer's
classes of common shares, as of the latest practicable date.
Common Shares, $.0167 Par Value 3,016,916 shares
- ------------------------------- ------------------------------------
(Title of Class) (Outstanding at December 6, 1999)
POLYDEX PHARMACEUTICALS LIMITED
TABLE OF CONTENTS
PAGE
----
PART I FINANCIAL INFORMATION
Item 1 CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Consolidated Balance Sheets
October 31, 1999 and January 31, 1999..............................3
Consolidated Statements of Operations
Three Months ended October 31, 1999 and 1998 and
Nine Months ended October 31, 1999 and 1998........................5
Consolidated Statements of Shareholders' Equity
and Comprehensive Income
Nine Months ended October 31, 1999 and 1998........................6
Consolidated Statements of Cash Flows
Nine Months ended October 31, 1999 and 1998........................7
Segmented Information
Three months ended October 31, 1999 and 1998 and
Nine months ended October 31, 1999 and 1998........................8
Item 2 MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS......................9
Item 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK..................................................14
PART II OTHER INFORMATION
Item 5 OTHER INFORMATION..................................................16
Item 6 EXHIBITS AND REPORTS ON FORM 8-K...................................17
Signatures.........................................................18
-2-
PART I
FINANCIAL INFORMATION
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED).
POLYDEX PHARMACEUTICALS LIMITED AND SUBSIDIARIES
Consolidated Balance Sheets
(Expressed in United States dollars)
- ---------------------------------------------------------------------------------------------------------------------------
(Unaudited)
October 31 January 31
1999 1999
- ---------------------------------------------------------------------------------------------------------------------------
ASSETS
Current assets:
Cash $ 245,238 $ 655,131
Trade accounts receivable 1,497,907 984,934
Inventories:
Finished goods 1,252,758 1,186,110
Work in process 111,928 53,023
Raw materials 762,288 678,145
-------------------------------------------------------------------------------------------------------------------
2,126,974 1,917,278
Prepaid expenses and other current assets 91,710 69,188
-----------------------------------------------------------------------------------------------------------------------
3,961,829 3,626,531
Property, plant and equipment, net 4,902,660 4,233,144
Patents, net 156,510 166,404
Due from Novadex Corp. - 658,574
Due from shareholder 1,515,001 903,037
Deferred income taxes 455,041 776,000
Other assets 69,521 92,574
- ---------------------------------------------------------------------------------------------------------------------------
$ 11,060,562 $ 10,456,264
- ---------------------------------------------------------------------------------------------------------------------------
- ---------------------------------------------------------------------------------------------------------------------------
-3-
- ---------------------------------------------------------------------------------------------------------------------------
(Unaudited)
October 31 January 31
1999 1999
- ---------------------------------------------------------------------------------------------------------------------------
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 1,314,604 $ 1,189,886
Accrued liabilities 630,819 466,556
Income taxes payable 60,460 51,779
Current portion of long-term debt 157,380 107,994
Current portion of mandatorily redeemable capital stock 75,000 100,000
-----------------------------------------------------------------------------------------------------------------------
2,238,263 1,916,215
Long-term debt 465,954 521,170
Due to shareholder 662,376 637,017
Deferred gain 647,824 659,018
Deferred income taxes 79,011 148,083
Mandatorily redeemable capital stock 225,000 300,000
- ---------------------------------------------------------------------------------------------------------------------------
Total liabilities 4,318,428 4,181,503
Redeemable capital stock (75,899 common shares; 99/01/31 - 93,899) 954,945 1,028,733
Shareholders' equity:
Capital stock:
Authorized:
100,000 Class A preferred shares of $0.10 each 899,400 Class B
preferred shares of $0.0167 each 10,000,000 common shares of
$0.0167 each
Issued and outstanding:
899,400 Class B preferred shares 15,010 15,010
2,941,018 common shares (99/01/31 - 2,923,018) 48,852 48,552
Contributed surplus 22,538,271 22,464,783
Deficit (16,079,146) (16,498,775)
Accumulated other comprehensive income (735,798) (783,542)
-----------------------------------------------------------------------------------------------------------------------
5,787,189 5,246,028
- ---------------------------------------------------------------------------------------------------------------------------
$ 11,060,562 $ 10,456,264
- ---------------------------------------------------------------------------------------------------------------------------
- ---------------------------------------------------------------------------------------------------------------------------
-4-
POLYDEX PHARMACEUTICALS LIMITED AND SUBSIDIARIES
Consolidated Statements of Operations (Unaudited)
(Expressed in United States dollars)
- -------------------------------------------------------------------------------------------------------------------------------
Quarter Ended Quarter Ended Year to Date Year to Date
October 31 October 31 October 31 October 31
1999 1998 1999 1998
- -------------------------------------------------------------------------------------------------------------------------------
Sales $ 3,674,392 $ 3,021,142 $ 9,872,318 $ 8,799,121
Cost of products sold 2,562,712 2,004,668 6,952,360 5,979,982
- -------------------------------------------------------------------------------------------------------------------------------
1,111,680 1,016,474 2,919,958 2,819,139
Expenses:
General and administrative 431,887 396,893 1,222,412 1,180,276
Research and development 186,608 23,214 430,124 98,312
Depreciation 124,399 117,629 374,555 335,361
Interest expense 44,476 37,773 115,863 104,109
Selling and promotion 33,479 20,661 86,350 104,610
Amortization 5,480 9,179 16,433 27,351
---------------------------------------------------------------------------------------------------------------------------
826,329 605,349 2,245,737 1,850,019
- -------------------------------------------------------------------------------------------------------------------------------
Income from operations 285,351 411,125 674,221 969,120
Other income:
Gain on sale of equipment - 3,894 - 11,140
Interest and other 7,818 4,601 24,118 45,785
---------------------------------------------------------------------------------------------------------------------------
7,818 8,495 24,118 56,925
- -------------------------------------------------------------------------------------------------------------------------------
Income before the undernoted 293,169 419,620 698,339 1,026,045
Provision for income taxes (77,020) (40,170) (278,710) (367,669)
- -------------------------------------------------------------------------------------------------------------------------------
Income for the period $ 216,149 $ 379,450 $ 419,629 $ 658,376
- -------------------------------------------------------------------------------------------------------------------------------
- -------------------------------------------------------------------------------------------------------------------------------
Per share information:
Earnings per common share for the period:
Basic $ 0.07 $ 0.13 $ 0.14 $ 0.22
Diluted $ 0.07 $ 0.13 $ 0.14 $ 0.22
- -------------------------------------------------------------------------------------------------------------------------------
Weighted average number of common shares
outstanding for the period 3,016,917 2,996,917 3,016,917 2,996,912
- -------------------------------------------------------------------------------------------------------------------------------
- -------------------------------------------------------------------------------------------------------------------------------
-5-
POLYDEX PHARMACEUTICALS LIMITED AND SUBSIDIARIES
Consolidated Statements of Shareholders' Equity and Comprehensive
Income (Unaudited)
(Expressed in United States dollars)
- -------------------------------------------------------------------------------------------------------
Year to Date Year to Date
October 31 October 31
1999 1998
- -------------------------------------------------------------------------------------------------------
Preferred Shares:
Balance, beginning of period $ 15,010 $ 15,010
Private placement of preferred shares - -
------------------------------------------------------------------------------------------------
Balance, end of period $ 15,010 $ 15,010
- -------------------------------------------------------------------------------------------------------
- -------------------------------------------------------------------------------------------------------
Common Shares:
Balance, beginning of period $ 48,552 $ 47,283
Sale of shares under purchase contingency 300 -
------------------------------------------------------------------------------------------------
Balance, end of period $ 48,852 $ 47,283
- -------------------------------------------------------------------------------------------------------
- -------------------------------------------------------------------------------------------------------
Contributed Surplus:
Balance, beginning of period $ 22,464,783 $ 21,826,025
Sale of shares under purchase contingency 73,488 -
------------------------------------------------------------------------------------------------
Balance, end of period $ 22,538,271 $ 21,826,025
- -------------------------------------------------------------------------------------------------------
- -------------------------------------------------------------------------------------------------------
Deficit:
Balance, beginning of period $ (16,498,775) $ (17,071,168)
Net income for the period 419,629 658,376
------------------------------------------------------------------------------------------------
Balance, end of period $ (16,079,146) $ (16,412,792)
- -------------------------------------------------------------------------------------------------------
- -------------------------------------------------------------------------------------------------------
Accumulated Other Comprehensive Income:
Balance, beginning of period $ (783,542) $ (665,768)
Currency translation adjustment for the period 47,744 (247,985)
------------------------------------------------------------------------------------------------
Balance, end of period $ (735,798) $ (913,753)
- -------------------------------------------------------------------------------------------------------
- -------------------------------------------------------------------------------------------------------
Comprehensive Income for the period:
Net income (loss) for the period $ 419,629 $ 658,376
Currency translation adjustment for the period 47,744 (247,985)
------------------------------------------------------------------------------------------------
$ 467,373 $ 410,391
- -------------------------------------------------------------------------------------------------------
- -------------------------------------------------------------------------------------------------------
-6-
POLYDEX PHARMACEUTICALS LIMITED AND SUBSIDIARIES
Consolidated Statements of Cash Flows
(Expressed in United States dollars)
- ------------------------------------------------------------------------------------------------------------------
Year to Date Year to Date
October 31 October 31
1999 1998
- ------------------------------------------------------------------------------------------------------------------
Cash provided by (used in):
Operating activities:
Net income for the period $ 419,629 $ 658,376
Add (deduct) items not affecting cash:
Depreciation and amortization 390,988 362,712
Deferred income taxes 265,160 367,669
Loss (gain) on sale of equipment - (11,140)
Legal expenses charged to deferred gain (11,194) (10,344)
Change in non-cash operating working capital (400,032) (197,439)
--------------------------------------------------------------------------------------------------------------
664,551 1,169,834
--------------------------------------------------------------------------------------------------------------
Investing activities:
Additions to property, plant and equipment and patents (1,050,613) (475,184)
Proceeds from sale of equipment - 11,140
--------------------------------------------------------------------------------------------------------------
(1,050,613) (464,044)
--------------------------------------------------------------------------------------------------------------
Financing activities:
Proceeds from loan payable - 15,835
Repayment of long-term debt (83,252) (50,412)
Proceeds from long-term debt 77,422 20,000
Payment of mandatorily redeemable capital stock (100,000) -
Proceeds from (repayment of) advances from shareholder, net 25,359 31,205
Repayment of advances to shareholder, net 46,610 (81,421)
Repayment of due to affiliated companies - (425,420)
--------------------------------------------------------------------------------------------------------------
(33,861) (490,213)
Effect of exchange rate changes on cash 10,030 (59,604)
- ------------------------------------------------------------------------------------------------------------------
Increase (decrease) in cash position (409,893) 155,973
Cash, beginning of period 655,131 288,527
- ------------------------------------------------------------------------------------------------------------------
Cash, end of period $ 245,238 $ 444,500
- ------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------
-7-
POLYDEX PHARMACEUTICALS LIMITED AND SUBSIDIARIES
Segmented Information (Unaudited)
(Expressed in United States dollars)
All operations are carried out through Dextran Products Limited
("Dextran") in Canada and through Chemdex, Inc. ("Chemdex") in the
United States. The operations of Chemdex represent the veterinary
products business and the operations are carried out through its
wholly-owned subsidiary, Veterinary Laboratories, Inc. Each of Dextran
and Chemdex operates as a strategic business unit offering different
products. Each subsidiary comprises a reportable segment as follows:
Dextran - manufactures and sells bulk
quantities of Dextran and several of
its derivatives to large
pharmaceutical companies throughout
the world.
Veterinary products - manufactures and sells veterinary
pharmaceutical products and
specialty chemicals in the United
States. The primary customers are
distributors and private labelers,
who in turn sell to the end-user of
these products.
- ------------------------------------------------------------------------------------------------------------------------------
Quarter Ended Quarter Ended Year to Date Year to Date
October 31 October 31 October 31 October 31
1999 1998 1999 1998
- ------------------------------------------------------------------------------------------------------------------------------
SALES:
Dextran $ 1,146,849 $ 928,461 $ 3,460,859 $ 3,111,225
Veterinary products 2,527,543 2,092,681 6,411,459 5,687,896
-----------------------------------------------------------------------------------------------------------------------
Total consolidated sales $ 3,674,392 $ 3,021,142 $ 9,872,318 $ 8,799,121
- ------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------
INCOME FROM OPERATIONS:
Dextran $ 283,534 $ 320,483 $ 850,986 $ 1,015,778
Veterinary products 210,062 230,829 392,717 458,461
-----------------------------------------------------------------------------------------------------------------------
Total income from operations from segments 493,596 551,312 1,243,703 1,474,239
Less: Unallocated corporate expenses 208,245 140,187 569,482 505,119
-----------------------------------------------------------------------------------------------------------------------
Total consolidated income from operations $ 285,351 $ 411,125 $ 674,221 $ 969,120
- ------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------
ASSETS:
Dextran $ 5,327,810 $ 4,226,176
Veterinary products 4,240,391 4,038,354
-----------------------------------------------------------------------------------------------------------------------
Total assets from segments 9,568,201 8,264,530
Corporate assets 1,492,361 1,557,009
-----------------------------------------------------------------------------------------------------------------------
Total consolidated assets $ 11,060,562 $ 9,821,539
- ------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------
-8-
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
POLYDEX PHARMACEUTICALS LIMITED AND SUBSIDIARIES
(a) RESULTS OF OPERATIONS
During the fiscal quarter ended October 31, 1999, the Registrant's pre-tax
income from operations amounted to $285,351, as compared to $411,125 for the
same period last year. This decline in results is due to a significant increase
in research and development expenditures as compared to the same quarter last
year. The vast majority of these research and development expenses are new
product development costs relating to the development of a raw material for a
human injectable product.
Operating profits during the quarter at Dextran Products Limited ("Dextran")
declined from $320,483 to $283,534, representing a decrease of $36,949 compared
to the same period last year. Operating profits at Veterinary Laboratories Inc.
("Vet Labs") declined from $230,829 to $210,062, representing a decrease of
$20,767 compared to the same period last year. The decline in operating profits
at both Dextran and Vet Labs is due to the new product development costs noted
above. At Vet Labs, however, this decline is partially offset by an overall
improvement in results driven by a significant sales increase.
Sales volume for the third quarter increased from $3,021,142 to $3,674,392,
representing an increase of $653,250 or 22%. This increase in sales volume is
attributable to an increase at Vet Labs of $434,862 and an increase at Dextran
of $218,385. Sales in the quarter at Vet Labs increased from $2,092,681 to
$2,527,543, representing a 10% increase. The injectable product line accounted
for almost the entire quarter over quarter sales increase at Vet Labs. Similar
to the first two quarters this year, there was a significant product mix
variance within the injectable product line. As in the first two quarters this
year, injectable iron dextran sales declined from the third quarter last year.
However, this reduction was more than offset by a substantial increase in sales
of other injectable vitamin products. Vet Labs continues to increase its market
penetration with these new injectable vitamin products. Towards the end of the
quarter, iron dextran sales levels began to increase. This trend is consistent
with the seasonality of this product and the general signs of economic recovery
in the Asian markets. Sales in the quarter at Dextran increased from $928,461 to
$1,146,849, representing a 24% increase. This quarter over quarter sales
increase is a result of increased demand for iron dextran.
Gross margins decreased from 34% in the third quarter in 1998 to 30% this
quarter. Dextran's quarter over quarter gross margin remained steady at 41%,
while Vet Labs' gross margin decreased from 23% to 19%. The decrease in margin
at Vet Labs is attributable to the decrease in injectable iron dextran
-9-
sales. This is one of the highest margin products at Vet Labs. However, the
diversification of the product lines and the addition of the injectable vitamin
products has helped considerably in maintaining margins at more consistent
levels. Management's on-going plan to develop new products and increase the
product offering is expected to continue to improve and stabilize the overall
margin levels at Vet Labs. The gross margin achieved at Vet Labs this quarter is
an improvement over the previous quarter this year and management expects this
trend to continue into the fourth quarter with continued improvement in iron
dextran sales. The gross margin achieved at Dextran this quarter is consistent
with that realized in the previous quarter this year.
Management expects strong demand to continue at Dextran. There will be some
minor production interruptions in the fourth quarter as new equipment is
installed and brought on line. This will likely result in decreased sales for
the quarter at Dextran because less orders will be filled. Summer months are
typically slower sales months for Vet Labs as large animals are put outdoors to
pasture and therefore have less need for vitamins and other supplements.
Consistent with this seasonality, higher sales levels and margins were
experienced at Vet Labs during the third quarter than during the previous
quarter. Management expects continued recovery in the hog markets in the coming
quarter and therefore anticipates higher injectable iron dextran sales.
Injectable vitamin sales in the third quarter were very strong and management
expects these sales to continue to be strong in the fourth quarter
General and administrative expenses have increased by $34,994 or 9% this quarter
as compared to the same quarter last year, primarily due to an increase in
management salary expense. In the third quarter last year, there was a reduction
in salary expense due to the departure of the former President of Chemdex, Inc.,
Natu Patel.
Research and development costs increased from $23,214 to $186,608 representing
an increase of $163,394 or 704% as compared to the third quarter last year due
to an increase in new product development costs relating to the development of a
raw material for a human injectable product. Development costs to date relating
to this project total approximately $332,000. Development costs for this product
are expected to continue for the remainder of the year.
Research and development, in conjunction with the Rush Institute of the
University of Chicago, relating to Cellulose Sulfate gel is progressing. Phase I
human clinical trials to test the safety and tolerance of this gel were
successfully completed. This trial was funded by the Consortium for Industrial
Collaboration in Contraceptive Research (CICCR). The project team is moving
ahead to prepare clinical supplies for long-term toxicology and phase II
clinical trials. Pre-IND tests have indicated that this gel holds great promise
as a topical prophylactic for sexually transmitted diseases, including AIDS, and
as a contraceptive. Management expects funding to continue from
-10-
CICCR for this project. No significant development expenditures relating to this
project are anticipated during the next quarter.
Selling and promotion expenses increased by $12,818 or 62% as compared to the
same period last year primarily due to the retention of a new investor relations
firm during the quarter.
There was no significant quarter over quarter changes in depreciation, interest
expense, or amortization expense.
Operating results for the third quarter ended October 31, 1999 are not
necessarily indicative of the results that may be expected for the year ended
January 31, 2000. For further information, refer to the consolidated statements
and footnotes thereto included in the Registrant's annual report on Form 10-K
for the year ended January 31, 1999.
(b) LIQUIDITY AND CAPITAL RESOURCES
During the third quarter, the Registrant generated cash flow from operations of
$570,745 compared to the prior year third quarter cash flow from operations of
$483,618. This increase of 18% is primarily attributable to a significant
increase in payables at Vet Labs during the quarter, which results in a large
increase in non-cash operating working capital. The increase in payables is
primarily a result of new product development costs incurred near the end of the
quarter.
There were small increases in receivables and inventory levels at both Dextran
and Vet Labs during the quarter, which partially offset the increase in payables
noted above. The increase in receivables is due to the increase in sales during
the quarter.
The majority of capital expenditures on plant and equipment during the quarter
related to engineering and construction costs for new production equipment at
Dextran. To date, plant refurbishment costs have been funded from working
capital. Financing arrangements have been negotiated with Dextran's bank to
finance a large piece of production equipment under a long-term capital lease
arrangement. The construction of this piece of production equipment will be
completed early in the fourth quarter and installation will take place
immediately thereafter. The bank financing, of approximately CDN $1,000,000 (USD
$675,000), will be advanced as soon as the equipment is operational. Management
has negotiated with Dextran's bank to temporarily increase the operating line of
credit from CDN $300,000 (USD $203,000) to CDN $1,000,000 (USD $675,000) during
the construction phase of this equipment. At October 31, 1999, CDN $960,000 (USD
$649,000) of this operating line remained available. The operating line will be
reduced once the long-term capital lease is put in place.
-11-
There will be some production interruption in the fourth quarter during the
installation of this equipment, which will likely reduce sales and margins at
Dextran during the quarter.
During the previous quarter, Novadex Corp., a company owned by the major
shareholder of the Registrant, was liquidated. All assets and liabilities of
Novadex Corp. were assumed by the major shareholder of the Registrant. The
transfer of the balance receivable from Novadex Corp. to the due from
shareholder account has not been reflected in the statement of cash flows as it
is a non-cash transaction. Included in the assets assumed by the major
shareholder of the Registrant is an exclusive worldwide license agreement with
the Registrant to use a certain process for producing iron dextran. The
Registrant will now pay this license fee to the major shareholder. These
payments will be applied to the balance owing by the major shareholder.
LONG-TERM OBJECTIVES
At the beginning of the year, two critical long-term objectives were identified.
1. Bring new products to market. During the first nine months of the year,
Cellulose Sulfate has completed Phase I human clinical trials, development
work has commenced on a raw material for a human injectable product and
Vet Labs continues development of new veterinary products.
2. Upgrade and refurbish existing production facilities to increase capacity
and efficiency. Refurbishment of the Dextran plant has commenced and
construction of the first new pieces of production equipment are nearing
completion.
YEAR 2000
The year 2000 issue refers to computer programs being written using two digits
rather than four to define an applicable year. A company's hardware, date driven
automated equipment or computer programs that have a two digit field to define
the year may recognize a date using "00" as the year 1900 rather than the year
2000. This faulty recognition could result in a system failure, disruption of
operations, or inaccurate information calculations. Similar to other companies,
the Company faces the challenge of ensuring that all of our computer related
functions will work properly from the year 2000 and beyond. The Company has
completed a detailed assessment of its systems, and does not believe that the
year 2000 computer issue will have a material adverse effect on the Company's
core business operations. Management expects transactions with customers,
suppliers, corporate partners and financial institutions to be fully supported
by the Company's systems.
While management believes its planning and preparations will be adequate and
complete well in advance of the year 2000, there can be no assurance that the
systems of suppliers and other companies on which the Company relies
-12-
will be year 2000 compliant on a timely basis, or that such failures by third
parties will not have a material adverse effect on the Company's business,
results of operations and financial condition. Management is in the process of
developing contingency plans that focus on reducing any disruption that might be
created by third parties with whom the Company does business being year 2000
non-compliant. Management does not expect the cost of its year 2000 initiative
to be material to the Company's results of operations or financial condition.
FORWARD-LOOKING STATEMENTS
This Form 10-Q, including the Management's Discussion and Analysis of Financial
Condition and Results of Operations, contains various "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended,
which represent the Company's expectations or beliefs concerning future events,
including, but not limited to statements regarding management's expectations of
regulatory approval and the commencement of sales and the sufficiency of the
Company's cash flow for the Company's future liquidity and capital resource
needs. In addition, statements containing expressions such as "believes",
"anticipates" or "expects" used in this Form 10-Q, the Company's Annual Report,
and the Company's periodic reports on Forms 10-K and 10-Q previously filed with
the Securities and Exchange Commission are intended to identify forward-looking
statements. The Company cautions that these and similar statements in this Form
10-Q, the Company's Annual Report, and in previously filed periodic reports
including reports filed on Forms 10-K and 10-Q are further qualified by
important factors that could cause actual results to differ materially from
those in the forward-looking statements. These factors include, without
limitation, changing market conditions, the progress of clinical trials, and the
results obtained, the establishment of new corporate alliances, the impact of
competitive products and pricing, and the timely development, FDA approval and
market acceptance of the Company's products, none of which can be assured.
Results actually achieved may differ materially from expected results included
in these statements as a result of these or other factors.
The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-Q and Article 10 of
Regulation S-X. Accordingly, they do not include all of the information and
footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, all adjustments (consisting
of normally recurring accruals) considered necessary for a fair presentation
have been included.
-13-
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
POLYDEX PHARMACEUTICALS LIMITED AND SUBSIDIARIES
OCTOBER 31, 1999
INTEREST RATE SENSITIVITY
The table below provides information about the Company's financial
instruments that are sensitive to changes in interest rates. All financial
instruments are held for other than trading purposes. The Company does not
have a material exposure to interest rate risk.
The table presents principal cash flows and related weighted average
interest rates by expected maturity dates.
Expected Maturity Date
------------------------------------------------------------------------------ Fair
31-Jan-00 31-Jan-01 31-Jan-02 31-Jan-03 31-Jan-04 Thereafter Total Value
--------- --------- --------- --------- --------- ---------- ----- -----
(US$ Equivalent)
ASSETS
Notes receivable:
Variable rate ($US) 64,529 66,979 18,201 19,611 21,131 599,111 789,563 789,563
Average interest rate 7.58% 7.66% 7.75% 7.75% 7.75% 7.75% 7.71%
LIABILITIES:
Long-term debt:
Fixed rate ($US) 8,866 348,386 - - - - 357,252 357,252
Average interest rate 8.79% 8.79% 0.00% 0.00% 0.00% 0.00% 8.79%
Fixed rate ($CDN) 22,761 97,578 113,652 6,653 - - 240,643 240,643
Average interest rate 9.06% 9.06% 9.04% 12.00% 0.00% 0.00% 9.79%
Variable rate ($US) 16,417 (39,998) (43,098) (46,438) (50,037) 850,510 687,357 687,357
Average interest rate 8.49% 7.75% 7.75% 7.75% 7.75% 7.75% 7.87%
-14-
POLYDEX PHARMACEUTICALS LIMITED AND SUBSIDIARIES
OCTOBER 31, 1999
EXCHANGE RATE SENSITIVITY
The table below provides information about the Company's financial
instruments that are sensitive to changes in foreign currency exchange
rates. All financial instruments are held for other than trading purposes.
The Company's major exposure to exchange rate risk is that the Canadian
dollar rises dramatically in relation to the U.S. dollar and that this
significantly reduces the gross margin experienced at Dextran Products.
Management monitors the margin at Dextran to ensure that an acceptable
margin level is maintained. Management has the ability, to some extent, to
adjust sales prices to maintain an acceptable margin level.
The table presents principal cash flows and related weighted average
interest rates by expected maturity dates.
Expected Maturity Date
------------------------------------------------------------------------- Fair
31-Jan-00 31-Jan-01 31-Jan-02 31-Jan-03 31-Jan-04 Thereafter Total Value
--------- --------- --------- --------- --------- ---------- ----- -----
(US$ Equivalent)
LIABILITIES:
Long-term debt:
Fixed rate ($CDN) 22,761 97,578 113,652 6,653 - - 240,643 240,643
Average interest rate 9.06% 9.06% 9.04% 12.00% 0.00% 0.00% 9.79%
-15-
PART II
OTHER INFORMATION
Item 5. Other Information.
The Registrant's proxies for its 2000 Annual General Meeting of the
Members will confer discretionary authority to vote on any matter if a
shareholder does not give written notice of the matter by April 3,
2000.
-16-
Item 6. Exhibits and Reports on Form 8-K.
(a) Exhibits
3.1 Memorandum of Association of Polydex Pharmaceuticals
Limited, as amended to date (filed as Exhibit 3.1 to
the Annual Report on Form 10-K filed April 30, 1997,
and incorporated herein by reference)
3.2 Articles of Association of Polydex Pharmaceuticals
Limited, as amended to date (filed as Exhibit 3.2 to
the Quarterly Report on Form 10-Q filed September 13,
1999, and incorporated herein by reference)
27 Financial Data Schedule
(b) Reports on Form 8-K
Not applicable.
-17-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: December 9, 1999
POLYDEX PHARMACEUTICALS LIMITED
(Registrant)
By \s\ George G. Usher
----------------------------------------
George G. Usher, Chairman, President
and Chief Executive Officer
(Principal Executive Officer)
By \s\ Sharon L. Wardlaw
----------------------------------------
Sharon L. Wardlaw, Treasurer, Secretary
and Chief Financial and Accounting
Officer (Principal Financial Officer)
-18-
EXHIBIT INDEX
Exhibit Number Exhibit Description
- -------------- -------------------
27 Financial Data Schedule